2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers

CovalX wishes to congratulate, Dr. James P. Allison and Dr. Tasuku Honjo, for receiving the 2018 Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.

Dr. James P. Allison and Dr. Tasuku Honjo have been working with the molecules CTLA-4 and PD-1 looking for new cancer treatments.

CTLA-4 and PD-1 are known as immune checkpoint inhibitors and the seminal discoveries by the two laureates have added a new pillar for the understanding of cancer.

CovalX is proud to have experience studying both of these molecules and related antibodies through our epitope mapping services:

Analysis of Ipilimumab, Nivolumab, and Pembrolizumab

Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in non-human primates and evaluation of local anti-CTLA-4 application

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1





Back